BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Go-ahead for PledPharma to Proceed With PLIANT Study Patient Recruitment


2/26/2013 11:25:52 AM

Stockholm, 2013-02-26 09:42 CET (GLOBE NEWSWIRE) -- DSMB has analyzed the test results from the first patient that was enrolled in the study two weeks ago. The study is in the initial stage, the so-called dose-escalation phase. The dosages of PledOx follow a strict protocol for when evaluating a new compound for the first time in a clinical trial. With the approval to proceed with the study, the first patient is to receive the second dose of PledOx, while the next two patients to be included in the study in parallel can receive the first low dose of PledOx. When all three patients received at least one cycle of therapy, and the first patient received three cycles DSMB will re-evaluate the data to give approval for this procedure to be repeated for the higher dose of PledOx.

Read at GlobeNewswire

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES